15 results about "PEG 400" patented technology

The invention relates to the field of spinning, and particularly discloses a polyester filament yarn preparation process which comprises the following steps: drying polyester chips, mixing the dried polyester chips with a hydrophilic agent, carrying out melt spinning to form nascent fibers, adopting a linear spinneret plate during spinning at the spinning speed of 4000-6000 m / min, carrying out traction treatment, carrying out heat setting treatment, carrying out alkali treatment, and winding to obtain the polyester filament yarn. Preparing polyester filament yarns; wherein the hydrophilic agent is a mixture of PEG (Polyethylene Glycol) 2000 and PEG 400 in a mass ratio of 1: (2-3). The preparation method has the characteristic that the prepared polyester filament yarn has better hygroscopicity and more excellent mechanical properties.

Nanoemulsion composition for the treatment of inflammatory bowel diseases, comprising: a) 1.0% (w / w) curcumin as active pharmaceutical ingredient; b) 10.0% w / w Caprylic / Capric triglycerides as oil phase; c) 15.0% w / w Tween 80 as surfactant; d) 10.0% w / w PEG 400 as co-surfactant; e) 2.0% w / w lecithin as emulsifier; f) 2.0% w / w ethanol as a solubilizer; and g) distilled water qs to 100 w / w, h) wherein the composition forms a nanoemulsion having a mean particle size in the range of 90-120 nm and a polydispersity index of less than 0.3 and provides sustained curcumin release for at least 12 hours in simulated intestinal fluid.

The invention discloses a preparation method of an intranasal targeted central nervous system drug, which comprises the following steps: dissolving chitosan in an acetic acid solution, and stirring to obtain a transparent chitosan solution with the concentration of 1.6-2.0% w / v; the preparation method comprises the following steps: adding ultra-pure water into poly (N-isopropylacrylamide) dry powder in a low-temperature state, slowly heating and stirring until the mixture is clarified, cooling to the low-temperature state, and complementing the mixture until the mass-volume ratio is 4-5.5% w / v; mixing the chitosan transparent solution and the poly (N-isopropylacryloyl) solution in a low-temperature state to generate a composite solution, and adding the beta-sodium glycerophosphate solution into the composite solution by using a micro pump to enable the volume ratio of the composite solution to the beta-sodium glycerophosphate solution to be (4: 1)-(5.5: 1); in a low-temperature state, dropwise adding a PEG400 pre-solution into the composite solution, so that the final concentration of the PEG400 reaches 0.05%-0.1% v / v; taking an exosome solution, slowly injecting the exosome solution into the composite solution at the speed of 2mL per minute, and continuously stirring to finally enable the exosome concentration to reach 80-150mu g / mL.

A novel compound complex that has no side effects on a liver and is used to alleviate the toxicity of an acetaminophen (APAP) drug to the liver. The composition of the compound consists of (a) acetaminophen in a pharmaceutically effective amount and (b) a commonly-used safe and pharmaceutically acceptable excipient that can be combined with one or more of two drugs to reduce the toxicity of a drug metabolized by the hepatic enzyme CYP2E1 in the liver.The compound is selected from the following group: Tween 20, microcrystalline cellulose, dicalcium phosphate, polyoxyethylene 23 lauryl ether, saccharin, mannitol, polyoxyethylene alkyl ether, sucralose, pyrrolidone, sodium starch glycolate, S100 acrylic resin, sodium carboxymethylcellulose, polyoxyethylene polyoxyethylene, menthol, low-substituted propylcellulose hydrocarbon, pregelatinized starch, Dextrates NF hydrate, citric acid, polyoxyethylene castor oil, colloidal silicon, aliphatic polyethylene glycol monostearate ester, sorbic acid, lemon oil, hydroxypropylcellulose, sorbitol, acesulfame potassium, hypromellose phthalate, lactose monohydrate, maltodextrin, Brij 58, Brij 76, Tween 80, Tween 40, PEG 400, Peg 4000, PEG 2000, and the like, so as to reduce the side effects caused by acetaminophen on the liver.

The invention discloses an antibacterial antioxidant degradable composite film for litchi preservation and a preparation method thereof, and mainly relates to the field of fruit and vegetable preservation. The adhesive is prepared by mixing polyvinyl alcohol (PVA), fumed silica (FS), polyethylene glycol 400 (PEG 400), melatonin (MT) and eugenol (EG). The method further comprises the following steps: S1, preparing a PVA solution; s2, adding PEG (Polyethylene Glycol) 400 into S1, and uniformly stirring; s3, weighing a certain amount of FS, MT and EG, and dissolving the FS, MT and EG in absolute ethyl alcohol; s4, adding the mixed solution in the step S3 into the mixed solution in the step S2, and homogenizing; and S5, carrying out defoaming, curtain coating and drying treatment on the solution treated in the step S4 to finally obtain the PVA / FS / MT / EG composite film. The method has the advantages that the method can be used as a physical barrier, color deterioration, browning and rotting of the Feizixiao litchis can be actively and effectively inhibited under normal-temperature and low-temperature conditions through the synergistic effect of active ingredients in the film, and the shelf life of the collected Feizixiao litchis can be well prolonged.

The application discloses application of SDDAB in improving the extraction performance of a PEG / sulfate aqueous two-phase system (ATPS), and specifically uses sulfobetaine surfactant 3-sulfopropyl dodecyl dimethyl betaine (SDDAB) to improve the extraction performance of a polyethylene glycol (PEG) / sulfate aqueous two-phase system for biological small molecules, and uses PEG 400 / (NH4)2SO4, PEG 400 / Na2SO4, PEG 4000 / (NH4)2SO4 and PEG 4000 / Na2SO4 aqueous two-phase systems with SDDAB as an additive to extract L-tryptophan (L-Trp) and vanillin (Van); effectively solve the problem of low extraction efficiency of the ATPS in extracting L-Trp and Van; and simultaneously realize the back extraction of L-Trp and Van to the lower phase of the ATPS by secondary back extraction, and has a high total recovery rate.

The application discloses anhydrous toothpaste and a preparation method thereof. The anhydrous toothpaste comprises a humectant, a thickening agent, an abrasive and an efficacy component; the humectant is composed of at least one of PEG 400 and propylene glycol and glycerol, and the amount of the glycerol is not more than 40% of the total weight of the anhydrous toothpaste; the thickening agent comprises microcrystalline cellulose; the abrasive is composed of at least one of calcium hydrogen phosphate dihydrate and calcium pyrophosphate and calcium hydrogen phosphate and hydrated silica, and the calcium hydrogen phosphate is the main abrasive; and the efficacy component comprises sodium monofluorophosphate and sodium phytate. The anhydrous toothpaste can improve the burning and irritating taste of the anhydrous toothpaste; the calcium hydrogen phosphate is used as the main abrasive, the sodium monofluorophosphate is used as a repairing and remineralizing component, the two components are compatible, the soluble fluorine concentration can be improved, and the tooth remineralization and acid erosion resistance can be ensured; and the microcrystalline cellulose thickening does not need to be neutralized and is resistant to high-speed shearing, so that the system damage caused by incompatible raw materials during the shelf life is avoided, and the stability is improved.

The present invention relates to a self-nanoemulsion drug release system comprising an oil phase and / or an emulsifier and / or a co-emulsifier. The oil phase is prepared from MCT 70, Labrafac Lipophile WL 1349, GTCC, IPM, Labrafil M 1944 CS, Labrafil M 2125 CS, Ethyl oil or any combination of the MCT 70, the Labrafac Lipophile WL 1349, the GTCC, the IPM, the Labrafil M 1944 CS, the Labrafil M 2125 CS and the Ethyl oil; the emulsifying agent is prepared from Tween 80, HS 15, Cremophor EL, Kolliphor ELP, Cremophor RH40 or any combination of the Tween 80, the HS 15, the Cremophor EL, the Kolliphor ELP and the Cremophor RH40; the co-emulsifier is prepared from PEG (Polyethylene Glycol) 200, Transcutol HP, Transcutol P, PEG 400 or any combination of the PEG 200, the Transcutol HP, the Transcutol P and the PEG 400. By utilizing the system, the solubility and permeability of the medicine can be improved, and the absorption of the medicine is enhanced.

This invention discloses an ethylene oligomerization catalytic system for reducing polymer adhesion and its application, belonging to the technical field of ethylene oligomerization for the preparation of α-olefins. The catalytic system includes a catalytic ligand, a transition metal compound, a co-catalyst, and an antistatic agent. The structural formula of the ligand is shown in Formula I. The antistatic agent is selected from one or more of the following substances: 8168 ashless antistatic agent, DuPont 450 antistatic additive, PEG 200, and PEG 400. Using this catalytic system for the preparation of α-olefins via ethylene oligomerization can effectively reduce the adhesion of by-product polymers in the reactor while maintaining high catalytic activity and high selectivity for 1-hexene and 1-octene, thereby extending the operating cycle of the unit and avoiding unplanned shutdowns for cleaning caused by adhesion.

The present application relates to the technical field of pharmaceutical preparation, and discloses a kind of quenching medicine composition for alcohol by regulating liver inflammation through NF-κB channel, including core active monomer consisting of quercetin, kaempferol and aloe emodin, HPMCAS-HF type skeleton network polymer, L-arginine, poloxamer 188, and by PEG 400 and deionized water composition transient mass transfer fluid, each raw material is made into amorphous powder by hot melt extrusion reaction through co-rotating twin-screw extruder.The processing temperature is reduced by the aid of transient mass transfer fluid plasticizing, and the degradation of active monomer by heat is avoided;The monomer is stabilized in amorphous form by polymer skeleton, and the local dissolution microenvironment is adjusted by L-arginine, which overcomes the defect of poor water solubility of natural monomer.The present application improves the dissolution and bioavailability of the drug, so that multiple components synergistically inhibit the NF-κB inflammatory pathway, and enhance the effect of quenching liver.

The invention relates to a formulation of topical or oromucosal gel for the treatment of disorders of skin and mouth. The formulation comprises misoprostol 1% dispersion, mineral oil, PEG 400-Part I. PEG 400-Part II and PEG 3350. The invention discloses formulations of two gels comprising 100 ug / g of misoprostol drug corresponding to a concentration of 0.01% and 30 ug of misoprostol drug corresponding to a concentration of 0.003% respectively. The formulation is effective against oral mucositis. RAS, diabetes foot ulcers, decubitus ulcers and skin burns. The animal studies indicate reduction of oral mucositis upon administration of the drug along with decrease in levels of biomarkers IL-6 and TNF-α and the body weight has been significantly maintained which indicate the drug to be safe and effective.

An adhesion material configured to be applied on a skin of a subject comprising a polymer molecular chain composition comprising polyethylene glycol 200 (PEG 200), polyethylene glycol 400 (PEG 400), citric acid, ascorbic acid, at least one of a sugar and a sugar alcohol, and at least one fatty acid.

The invention belongs to the field of cleaning agents, and particularly relates to a cleaning agent and a preparation method and application thereof.The cleaning agent is prepared from, by weight, 0.2%-0.6% of sodium carbonate, 0.4%-1% of sodium bicarbonate, 1%-2% of secondary alkyl sodium sulfonate, 1%-1.5% of polyhydric alcohols, 1%-1.5% of chitosan derivatives, 0.3%-0.8% of cyclodextrin derivatives, 0.8%-1.2% of PEG-400, 1%-1.5% of maltitol, 0.5%-0.8% of methyl oleate, 0.03%-0.05% of silyl ether defoaming agents and the balance water; the silyl ether defoaming agent comprises the following raw materials: dimethyl siloxane, polyether, a catalyst, ethanol, fatty acid amide containing benzene rings, modified diatomite and deionized water. The cleaning agent provided by the invention has the advantages of better cleaning effect, lower corrosivity, higher stability, difficulty in bubble generation, environment friendliness, easiness in degradation and the like, and has a better application prospect.

Certain embodiments of the present disclosure provide storage-stable, aqueous pharmaceutical formulations, suitable for oral administration, that contain a therapeutically effective amount of that is from 2% w / v to 7.5% w / v topiramate, from 45% w / v to 75% w / v PEG 400, from 6% w / v to 12% w / v water, balance glycerol. In some embodiments, such formulations further comprise a sweetener (e.g., sucralose) and / or a flavorant (e.g., berry flavor).

The invention belongs to the field of flexible materials, and particularly relates to an organic silicon flexible material and a preparation method thereof.The organic silicon flexible material is prepared from, by weight, 60-80 parts of acrylic acid modified siloxane, 10-30 parts of plant fiber, 2-6 parts of silane coupling agent, 2-5 parts of photoinitiator and 0.5-4 parts of PEG 400, and after siloxane is modified through acrylic acid, the organic silicon flexible material is added into the organic silicon flexible material; the crosslinking density and the mechanical property are remarkably improved, and an acrylic acid group and a functional group of a silane modified layer on the surface of the plant fiber are connected through a photocuring reaction, so that efficient interface bonding is realized, and the overall strength and toughness of the organic silicon material are further improved; besides, optical transparency of the material can be achieved through the photocuring effect, environmental pollution caused by a traditional curing agent is avoided, and powerful functional material support is expected to be provided for complex intelligent application of electronic skin, biosensors, soft robots and the like.